TY  - JOUR
AU  - Megias-Vericat, Juan Eduardo
AU  - Martinez-Cuadron, David
AU  - Martinez-Lopez, Joaquin 
AU  - Bergua, Juan Miguel
AU  - Tormo, Mar
AU  - Serrano, Josefina
AU  - Gonzalez, Ataulfo
AU  - Perez-de-Oteyza, Jaime 
AU  - Vives, Susana
AU  - Vidriales, Belen
AU  - Herrera, Pilar
AU  - Vera, Juan Antonio
AU  - Lopez-Martinez, Aurelio 
AU  - de-la-Fuente, Adolfo
AU  - Amador, Ma Lourdes
AU  - Hernandez-Rivas, Jose-Angel
AU  - Fernandez, Ma Angeles
AU  - Cervero, Carlos Javier
AU  - Morillo, Daniel
AU  - Hernandez-Campo, Pilar 
AU  - Gorrochategui, Julian
AU  - Primo, Daniel
AU  - Rojas, Jose Luis
AU  - Guenova, Margarita
AU  - Ballesteros, Joan
AU  - Sanz, Miguel
AU  - Montesinos, Pau
PY  - 2019
DO  - 10.4084/MJHID.2019.016
SN  - 2035-3006
UR  - http://hdl.handle.net/10668/13689
T2  - Mediterranean journal of hematology and infectious diseases
AB  - Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates....
LA  - en
PB  - Mattioli 1885 SpA
KW  - Acute myeloid leukemia
KW  - Anthracycline
KW  - Daunorubicin
KW  - Idarubicin
KW  - Mitoxantrone
KW  - Personalized medicine
KW  - ex-vivo test
KW  - Bone Marrow
KW  - Induction Chemotherapy
KW  - Leukemia, Myeloid, Acute
KW  - Antibiotics, Antineoplastic
KW  - Drug Combinations
TI  - Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.
TY  - research article
VL  - 11
ER  -